Kevin C. Gorman
2017
In 2017, Kevin C. Gorman earned a total compensation of $7.6M as Chief Executive Officer at Neurocrine Biosciences, a 43% increase compared to previous year.
Compensation breakdown
| Bonus | $515,200 |
|---|---|
| Option Awards | $4,929,898 |
| Salary | $640,000 |
| Stock Awards | $1,426,920 |
| Other | $44,356 |
| Total | $7,556,374 |
Gorman received $4.9M in option awards, accounting for 65% of the total pay in 2017.
Gorman also received $515.2K in bonus, $640K in salary, $1.4M in stock awards and $44.4K in other compensation.
Rankings
In 2017, Kevin C. Gorman's compensation ranked 1,038th out of 14,666 executives tracked by ExecPay. In other words, Gorman earned more than 92.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,038 out of 14,666 | 93rd |
Division Manufacturing | 352 out of 5,770 | 94th |
Major group Chemicals And Allied Products | 93 out of 2,074 | 96th |
Industry group Drugs | 62 out of 1,730 | 96th |
Industry Biological Products, Except Diagnostic Substances | 10 out of 316 | 97th |
Source: SEC filing on April 17, 2019.
Gorman's colleagues
We found four more compensation records of executives who worked with Kevin C. Gorman at Neurocrine Biosciences in 2017.
News
Neurocrine Biosciences CEO Kevin Gorman's 2021 pay rises 1% to $14M
April 7, 2022
Neurocrine Biosciences CEO Kevin Gorman's 2020 pay jumps 47% to $14M
April 9, 2021
Neurocrine Biosciences CEO Kevin Gorman's 2019 pay rises 9% to $9.5M
April 9, 2020
Neurocrine Biosciences CEO Kevin Gorman's 2018 pay rises 14% to $8.6M
April 17, 2019